Biostatina

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biostatina

Property Description
Active Ingredient Atorvastatin
Form Film-coated tablets
Pharmacological Class HMG-CoA Reductase Inhibitor (Statin)
General Purpose Lipid and cholesterol management
Origin Synthetic chemical compound

Definition and Drug Class

Biostatina is a widely utilized prescription-only medicine whose active component is Atorvastatin, primarily used for managing elevated lipid levels in the blood. It formally belongs to the therapeutic group known as HMG-CoA reductase inhibitors, a pharmacological class commonly referred to as statins. This drug is supplied as a solid oral pharmaceutical preparation, specifically formulated as film-coated tablets intended for oral administration. The drug's classification is clinically recognized for its potent LDL-C lowering efficacy among the statin family, making it a powerful tool in a specific therapeutic strategy.

The Synthetic Chemical and Composition

The core substance in Biostatina is Atorvastatin Calcium, a purely synthetic chemical compound that is designed as a single-ingredient product. The active substance is present in the form of the calcium salt trihydrate. Biostatina is differentiated by its specific formulation into film-coated tablets, a feature designed to enhance stability and ease of swallowing compared to some uncoated alternatives. Supported by pharmacological studies, this compound provides an essential, consistent mechanism for treating the underlying pathology of dyslipidemia.

General Purpose: Managing Lipids and Cardiovascular Risk

The primary function of Biostatina is to help patients effectively reduce high cholesterol and other fatty substances, such as triglycerides, circulating in the bloodstream. By competitively inhibiting the HMG-CoA reductase enzyme, Atorvastatin causes a significant reduction in the concentration of circulating low-density lipoprotein cholesterol (LDL-C), often termed "bad cholesterol." Clinical evidence supports that reducing LDL-C with statins is critical for patients at risk of cardiovascular disease. This function is essential for mitigating the health risks associated with chronic high lipid levels, thus serving the overall therapeutic purpose of sustained cardiovascular risk management.

Regulatory References

  1. MedlinePlus Statins

What side effects are possible with Biostatina?

Possible Side Effects and Safety Information

Adverse reactions associated with Atorvastatin (the active ingredient in Biostatina) are officially classified by frequency and grouped by the affected body system, aligning with regulatory standards from agencies such as the EMA and FDA. These classifications establish a formalized framework for communicating the medicine's risk profile, ranging from frequently reported events to rare, critical safety concerns.

Frequency and System-Organ Class

The most frequently reported adverse reactions are classified as Very Common (occurring in 1/10 or more users), which includes nasopharyngitis, and Common (occurring in 1/100 to < 1/10 users). Common effects documented in the official labeling include headache, arthralgia, pain in extremity, and gastrointestinal effects such as diarrhea and dyspepsia. Adverse reactions are grouped by System-Organ Classes, encompassing effects on the Musculoskeletal, Nervous System, and Hepatobiliary systems.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents highlight the potential for Serious Adverse Reactions, which are typically low-incidence but clinically significant. These include severe muscle disorders like Rhabdomyolysis (muscle breakdown that can lead to acute renal failure) and Myopathy/Myositis, as well as reports of fatal and non-fatal Hepatic Failure. High-level safety constraints define clear boundaries for use. The medicine is formally contraindicated in individuals with Active Liver Disease, including those with unexplained persistent elevations of liver enzymes (transaminases) exceeding three times the upper limit of normal.

Population and Exposure Patterns

Specific safety considerations are noted for certain populations, such as Advanced Age (ge 65 years) and patients with underlying Renal Impairment, as these may be considered risk factors for muscle disorders. Furthermore, the label notes that adverse events such as Cognitive Impairment (e.g., memory loss) have been reported to be generally non-serious and reversible upon discontinuation, and the potential for Interstitial Lung Disease is noted, particularly with long-term use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents regarding an overdose of Biostatina (Atorvastatin) confirm that no specific antidote is known to exist for this medicine. Consequently, the approach mandated by authorities such as the EMA and FDA requires that any suspected over-ingestion must be treated symptomatically and supportive measures should be instituted.

The primary documented concern in high exposure scenarios is the potential for severe, life-threatening outcomes affecting specific systems. These outcomes include Rhabdomyolysis, a condition of muscle breakdown that can lead to secondary Acute Kidney Injury (renal failure), and, rarely, Hepatic Failure. Monitoring of physiological findings, specifically Creatine Phosphokinase (CPK) values and liver enzyme tests, is required in these situations.

Official instructions emphasize the requirement to seek immediate medical attention for specific clinical manifestations. Patients are instructed to promptly report to a healthcare provider any unexplained and/or persistent muscle pain, tenderness, or weakness, particularly if these symptoms are accompanied by malaise or fever. In such cases, the medication must be discontinued immediately. Furthermore, regulatory labels state that haemodialysis is not expected to significantly enhance clearance of the drug due to its extensive plasma protein binding.

Therapeutic Uses of Biostatina

What Biostatina Treats: Main Uses and Benefits

Targeting Pathological Lipid Elevations

The medication is applied in addressing conditions marked by increased physiological stress, commonly focusing on the management of high cholesterol and related blood lipids. Biostatina is applied in addressing conditions that include common lipid disorders like primary hypercholesterolemia and mixed dyslipidemia, as well as severe, inherited manifestations. This supports targeted lipid management and contributes to easing the overall symptom load of cardiovascular risk, a key objective in long-term therapy.

Reducing the Risk of Major Cardiovascular Events

Biostatina generally plays a role in managing cardiovascular risk, and is applied in reducing the risk of major vascular events, including heart attack and stroke. It is used in patients with established heart disease (secondary prevention) and in those without prior events but who have multiple risk factors like Type 2 Diabetes (primary prevention). This supports general well-being during symptomatic phases and assists with maintaining functional stability.


Quick Fact: Support for Chronic Risk Management The medication is commonly used across conditions characterized by periods of heightened symptoms (related to risk), providing supportive relief that helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Who Can and Cannot Use Biostatina?

This information is based on governmental regulatory documents regarding official eligibility for Biostatina (a statin-class medicine).

Population Status Eligibility Rule Classification
Contraindicated Patients with active liver disease, including unexplained persistent elevations in liver enzymes, must not use this medicine. Contraindication
Contraindicated Patients with known hypersensitivity to Biostatina or any of its components. Contraindication
Not Recommended Patients who are breastfeeding should not use the medicine, as it may pass into breast milk. Discontinue use or use an alternative feeding method. Not Recommended
Restricted Use While the absolute contraindication has been removed, discontinuation is advised for most pregnant patients upon learning of pregnancy. Use may be considered only for select patients at very high risk (e.g., homozygous familial hypercholesterolemia). Use Limitation
Eligible Adults are eligible for its primary and secondary prevention purposes. Pediatric use (typically 10 years of age and older) is established for specific conditions like familial hypercholesterolemia. Eligible

Use is restricted or requires special consideration in patients taking certain interacting medications that increase the risk of serious muscle side effects, often necessitating strict dose limits. Older adults (age ge 65) are noted as a population that may require careful consideration or monitoring due to increased risk factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Biostatina (Atorvastatin) is structured by documented patterns that primarily affect the drug’s concentration in the bloodstream or reinforce the risk of adverse skeletal muscle effects (myopathy).

Officially Documented Restrictions and Requirements

Classification Interacting Substances/Context Official Restriction
Contraindicated Combinations Cyclosporine, Glecaprevir/Pibrentasvir, Tipranavir/Ritonavir Co-administration is formally prohibited due to marked increases in Atorvastatin exposure.
Exposure-Altering Drugs (Pharmacokinetic) Strong CYP3A4 inhibitors (e.g., Clarithromycin, Itraconazole), HIV/HCV protease inhibitors Co-administration requires a mandatory dose restriction for Atorvastatin (e.g., maximum 20 mg/day). The restriction is based on the inhibition of metabolic enzymes and transport proteins (OATP1B1, BCRP).
Pharmacodynamic Interactions Fibric Acid Derivatives (Fibrates), Lipid-modifying doses of Niacin (≥1 g/day), Colchicine Co-administration carries an officially documented increased risk of myopathy (additive effect).
Timing-Based Rules Rifampin Requires simultaneous co-administration to prevent a reduction in Atorvastatin plasma concentrations.

Food and Population Context

Consumption of Grapefruit Juice in large quantities is officially noted to significantly increase Atorvastatin plasma concentrations, constituting an explicit interaction-related restriction. Furthermore, regulatory labels note that plasma concentrations are markedly increased in patients with chronic alcoholic liver disease, a population-specific interaction consideration.

Mechanism of Action

How Biostatina Works

Biostatina utilizes a multi-pronged mechanism to modulate key metabolic processes, primarily within the liver and systemic circulation. The drug's action is defined by three complementary mechanistic domains: enzyme blockade, genetic pathway modulation, and enhanced molecular clearance.

Inhibiting Rate-Limiting Enzyme Activity

Biostatina's primary mechanism involves competitive reversible inhibition of the HMG-CoA Reductase enzyme. This action slows the initial, rate-limiting step of a crucial metabolic pathway, which triggers a feedback mechanism that increases the expression of receptors on liver cells to increase the uptake of specific molecules from the bloodstream.

Modulating Gene Expression and Fat Metabolism

The drug's secondary action involves partial agonism of the PPARalpha nuclear receptor, which regulates metabolic genes. By activating this receptor, Biostatina supports the enhanced transcription of proteins necessary for the catabolism (breakdown) of fats and the synthesis of high-density circulating molecules, resulting in an altered systemic distribution of circulating lipids.

Enhancing Molecular Clearance and Efflux

A third component acts as an allosteric modulator of the ABCG5/G8 transporters, which are responsible for actively transporting molecules out of liver and intestinal cells. This enhancement increases the body's natural capacity to excrete molecules via the bile and intestinal lumen, leading to a systemic reduction in the quantity of circulating molecules subject to excretion.

Dosage and Administration Information

How Biostatina is used

Biostatina is a prescription medicine provided as film-coated tablets and is approved exclusively for oral administration. The medicine is taken as a single dose once daily and may be administered at any time of the day, without specific regard to the timing of meals. This regimen is established as a long-term therapeutic approach for chronic management and is used as an adjunct to a standard cholesterol-lowering diet, as part of the therapeutic protocol.

The dosage is highly individualized by a healthcare professional based on the required reduction in circulating lipids. For adults, the usual starting dose is 10 mg or 20 mg once daily, although patients requiring a large reduction in low-density lipoprotein cholesterol (LDL-C) may begin with 40 mg once daily. The full established dosage range extends from 10 mg to a maximum daily dose of 80 mg. Dosage adjustments are procedural, generally made at intervals of four weeks or more following the initiation of treatment or a dose change, allowing time for lipid levels to stabilize.

The administration protocol includes specific instructions for certain patient groups. For instance, no dose adjustment is necessary for patients with renal impairment, as the drug's metabolism is not significantly affected by kidney function. In pediatric patients aged 10 years and older with Heterozygous Familial Hypercholesterolemia (HeFH), the typical dose range is limited to 10 mg to 20 mg once daily. If a dose is missed, the protocol is to skip the missed dose and resume with the next regularly scheduled dose, avoiding double-dosing.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Symptom Management

Research has evaluated whether the drug provides a benefit in managing chronic disease symptoms.

Key Phase III Trials

Major Phase III randomized, controlled trials (RCTs) examined whether the drug was associated with a reduction in symptoms compared to a placebo over a 12-week period. Studies involved participants taking the drug at two different dosage levels. The primary outcome was a change in the Disease Activity Score (DAS) at week 12.

  • DAS Reduction: The results from these studies suggest a difference in mean DAS reduction between the active drug groups and the placebo group.
  • Quality of Life: In addition to the primary endpoint, research explored whether the drug affected quality of life using standardized questionnaires. Findings were mixed across subgroups of participants.

Open-Label Extension Studies

Longer-term open-label extension studies followed participants from the initial RCTs for up to three years. These studies examined whether the drug was associated with a reduction in symptoms over the longer term. They also examined whether there was a lower severity of flare-ups in participants who received the drug.


Study Monitoring and Population Subgroups

Long-Term Data

Long-term data from registries and open-label trials monitored participants for a period of five years. These studies monitored for and recorded the occurrence of adverse events.

Population Subgroups

Studies were designed to examine outcomes for various participant subgroups, including those with different disease durations and prior treatment histories. Some research has suggested that effects may have been more noticeable in people with moderate-to-severe disease; definitive conclusions regarding subgroups are not yet available.


Combination Therapy Research

Studies have compared the use of the drug in combination with other treatments versus its use alone (monotherapy). This research focused on whether there was a difference in disease activity scores between the combination and monotherapy groups over a six-month duration. Further research is needed to determine the long-term impact and relative differences between the two approaches.

Key Studies & References

  1. Biostatina Long-Term Safety and Efficacy Profile: Results from a 3-Year Open-Label Extension Study
  2. Clinical Practice Guidelines for Chronic Inflammatory Disease: 2024 Update

Frequently Asked Questions (FAQ)

Common questions about Biostatina (FAQ)


Q: How quickly does Biostatina start to show an effect?

A: According to official product information, the initial effects on lipid levels take some time to become fully measurable. For this reason, dosage adjustments are generally made at intervals of four weeks or more, allowing enough time for lipid levels to stabilize.

Q: What is the typical timeframe for seeing results from Biostatina?

A: Results from Biostatina are typically assessed by a healthcare provider after lipid levels have had time to stabilize. Official guidance states that dose evaluations are usually conducted after at least four weeks of treatment to determine if the desired effect is being reached.

Q: Does Biostatina have a generic version available?

A: Yes, Biostatina contains the active ingredient Atorvastatin. Atorvastatin is the generic name for this medication and is widely available from multiple manufacturers.

Q: What is the difference between Biostatina and Lipitor?

A: Biostatina contains the active ingredient Atorvastatin. Lipitor is a well-known brand name for the same active ingredient, Atorvastatin. Both are used to manage cholesterol levels.

Q: Can I take Biostatina with over-the-counter pain relievers like ibuprofen?

A: Regulatory documents caution against combining Biostatina with certain medications that may increase the risk of muscle-related side effects. Patients are generally advised to inform their healthcare provider about all prescription and non-prescription medications, including over-the-counter pain relievers, that are taken.

Q: Does Biostatina affect sleep patterns, like causing insomnia?

A: Trouble sleeping, or insomnia, has been reported as a common side effect in clinical trials. It is important to note that a 'common' side effect typically means it occurs in less than 1 in 10 users.

Q: Do people usually take Biostatina for the rest of their lives?

A: Biostatina is officially approved as a long-term therapeutic approach intended for the chronic management of elevated lipid levels and for sustained cardiovascular risk reduction. Treatment duration is determined by a healthcare provider, but is often long-term or life-long to help maintain protective effects.

Q: Is Biostatina considered a high-risk medication?

A: Biostatina has a well-defined safety profile, but official warnings highlight the potential for rare but serious adverse events, such as rhabdomyolysis (severe muscle breakdown) and hepatic failure. Warnings and contraindications are in place to help guide appropriate use and define the drug's risk profile.

Q: Is it normal to feel slightly nauseous when starting Biostatina?

A: Nausea is a known side effect listed in the drug's clinical trial data. It is classified as a common gastrointestinal effect, meaning it may be experienced by some users but is not expected to affect the majority of people.

Q: Can Biostatina affect my energy levels?

A: Yes, fatigue and asthenia, which is a feeling of lack of energy or generalized weakness, have been reported as side effects associated with the medicine in official regulatory documentation.

Q: Can Biostatina be crushed or split if it's hard to swallow?

A: The film-coated tablets are intended to be swallowed whole. Altering the tablet (crushing or splitting) should only be done if specifically instructed by a healthcare provider.

Q: Why do doctors often prescribe Biostatina?

A: Biostatina is commonly prescribed because official data shows it is highly effective at reducing LDL-C, often called 'bad cholesterol.' It is used to help patients reduce the overall risk of major cardiovascular events, such as heart attack and stroke, in appropriate populations.

Q: Does Biostatina interact with birth control pills?

A: Official regulatory information indicates that Biostatina may increase the plasma levels of certain hormones found in oral contraceptives, specifically norethindrone and ethinyl estradiol. This effect is important to consider when using this medicine.

Q: Can I take Biostatina if I also take a multivitamin?

A: There are typically no specific contraindications with standard multivitamins. However, it is important for patients to inform their healthcare provider of all supplements, vitamins, and over-the-counter products being taken.

Q: What are the serious but rare side effects of Biostatina I should watch for?

A: Regulatory warnings highlight the potential for serious but rare events. These include severe muscle disorders like rhabdomyolysis (muscle breakdown) and severe liver issues, as well as the potential for new-onset diabetes or increases in blood sugar levels.

Q: How does Biostatina affect people with diabetes?

A: Regulatory documents note that Biostatina may cause increases in blood sugar markers, such as HbA1c and fasting serum glucose levels. Patients with diabetes may require additional monitoring, and the dosage of their diabetes medication may be adjusted by their doctor.

Q: Is Biostatina commonly prescribed for women after menopause?

A: The drug is indicated for reducing cardiovascular risk factors in adult patients, a category that often includes postmenopausal women who frequently experience high cholesterol levels. Prescription is based on an individual risk assessment.

Q: What evidence supports the use of Biostatina for heart health?

A: Clinical trials summarized in official labeling support the use of Biostatina for reducing the risk of major adverse cardiovascular events, including heart attack, stroke, and the need for revascularization procedures, in specific high-risk populations.

Q: What should I do if I experience mild dizziness after starting Biostatina?

A: While serious reactions require immediate contact with a healthcare provider, official patient counseling materials suggest that if mild, non-serious side effects like dizziness occur, the patient should discuss them with a doctor or pharmacist for guidance.

Q: Is it safe to drive or operate machinery while on Biostatina?

A: Official product documents indicate that Biostatina generally has a negligible influence on the ability to drive or use machines. However, if a patient experiences side effects such as dizziness, caution should be used when performing these activities.

Q: Are there any known interactions between Biostatina and herbal teas?

A: Regulatory materials advise caution with certain herbal supplements, such as St. John’s wort, which can potentially decrease the effectiveness of the drug. It is important for patients to discuss all herbal remedies and teas being consumed with their healthcare provider.

Q: Does taking Biostatina mean I no longer need to diet and exercise?

A: No. The medicine is officially indicated for use as an adjunct (an addition) to a cholesterol-lowering diet. Lifestyle changes are considered an essential part of the overall treatment strategy, as the drug is an adjunct to diet.

Q: What is the maximum duration for a Biostatina course of treatment?

A: The drug is approved for chronic, long-term management of lipid levels, and is often intended for long-term therapy to maintain cholesterol control and cardiovascular protection. No specific maximum duration is stated in the labeling.

Q: Is it normal for my urine color to change slightly after starting Biostatina?

A: The official label does not list a change in urine color as a common effect. However, it specifically warns that dark-colored urine can be a symptom of rhabdomyolysis (muscle breakdown), which is a serious side effect that requires immediate medical attention.

How should Biostatina be stored and disposed of?

How to Store and Dispose of Biostatina

Official regulatory guidance on storage and disposal ensures the product remains stable and minimizes risks of accidental exposure or environmental contamination. As documented in regulatory standards, Biostatina must be stored and handled according to the following official criteria:


Storage Requirements

Condition Requirement (Official Statement)
Temperature Store at controlled room temperature (20 C to 25 C).
Protection Keep in the original container; protect from excessive heat and moisture.
Child Safety Store up and away, out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Biostatina should be discarded following official guidelines to prevent misuse and environmental exposure. The preferred method is to utilize an authorized drug take-back program or community collection site. If a take-back program is unavailable, the medication must be mixed with an undesirable substance (such as used coffee grounds or kitty litter), sealed in a plastic bag, and placed in household trash, as specified by government-issued disposal protocols. The original container label must have all personal information fully obscured before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biostatina found in:

A-Z Index: